Abstract-The antagonistic effect of etizolam, an anti-anxiety drug, on platelet activating factor (PAF) was investigated in rabbit platelets in vitro. Etizolam inhibited PAF-induced aggregation in a dose-dependent manner, with an IC50 of 3.8 /iM, about one tenth that of triazolam (IC50=30 uM). At 300 ,oM, it in hibited both ADP and arachidonic acid-induced aggregation only slightly, while the other anti-anxiety drugs tested had no effect on PAF-induced aggregation even at this concentration. Etizolam and triazolam inhibited the specific binding of 3H-PAF to PAF receptor sites on washed rabbit platelets with IC50 values of 22 nM and 320 nM, respectively. Diazepam and estazolam were inactive even at 1 ,iM. These results indicate that etizolam is a specific antagonist of PAF.
The psychotropic benzodiazepine drugs alprazolam and triazolam have been reported to inhibit specifically platelet-activating factor (PAF)-induced platelet aggregation (1) . Etizolam (Depas®), a thienodiazepine drug used as an anti-anxiety agent (2, 3), has a chemical structure similar to that of triazolam.
Its inhibitory effects on PAF induced bronchoconstriction, PAF-induced hypotension and PAF-induced mortality in vivo were reported in a previous paper (4 by centrifuging the blood at 200 g for 10 min, and PPP was made by centrifuging at 1400 g for 10 min. Washed platelet suspensions were prepared from PRP. PRP was sedi mented with equal volumes of standard platelet buffer (3.2 mM KH2PO4, 4.8 mM Na2H PO4, 80 mM citric acid, 4.4 mM glucose, pH 6.5) at 1000 g for 10 min at 4°C. The pellets were resuspended in the same buffer as above and centrifuged at 1400 g for 5 min at 4°C. This procedure was repeated 3 times. The platelet pellets were finally resuspended in standard platelet buffer containing 0.9 mM CaCl2 and 0.1% bovine serum albumin (BSA) at a concentration of 1.1 x 108 platelets/ml.
4. Assay for platelet aggregation: Ag gregation was measured at 370C with a turbidimetric device (N KK Hematracer 1, model PAT-6A, Niko Bioscience, Tokyo, Japan) by a previously described method (5). Inhibition of platelet aggregation was as sessed by comparing the maximal change in transmitted light in drug-treated PRP with that in vehicle treated PRP. The aggregometer was adjusted in sensitivity to give light transmission values of 0 and 100% for PRP and PPP, respectively. The aggregating agents were used at the minimal concentration which induces maximal aggregation.
5. Assay for receptor binding: The experi ments were done according to the method of Valone (6) with a slight modification. A 920 tl aliquot of buffer containing 108 platelets were added to siliconized tubes containing 40 Id of test compound solution and preincubated for 5 min at 25'C. The binding reaction was begun by adding 40 ,ul of 3H-PAF (8 nM) to the tubes at 25°C and stopped by adding 4 ml of ice-cold saline containing 0.1% BSA (washing solution). Platelets were isolated by vacuum filtration through glass filters (Whatman GF/F filter, England). The filters were rapidly washed 4 times with 4 ml of ice-cold washing solution, and the radioactivity was measured in 4 ml of ACS-II scintillator (Amersham, England) with a scintillation counter (model 3380, Packard, U.S.A. 1 ). Among the compounds tested, it was the most potent inhibitor of PAF-induced ag gregation and about 10 times more potent than triazolam (IC50=30.0 ,aM). Other anti anxiety drugs tested had no effect on PAF induced aggregation (Fig. 2, Table 1 ).
2. PAF receptor binding: The time course for 3H-PAF binding to rabbit platelets showed an increase in radioactivity associated with the platelets. Specific binding reached half maximal values in 5 min, and approximate steady-state binding was achieved after a 10 min incubation. Therefore, we used an incubation time of 10 min in subsequent studies. Unlabelled PAF (1 PM) reversed the specific binding of 3H-PAF in a time dependent manner. Three min after the addition of PAF, the specific binding of 3H PAF was almost completely displaced (Fig.  3) . Figure 4 shows the inhibition percentages of the test compounds on the specific binding of 3H-PAF to the PAF receptor sites in the platelets. Etizolam inhibited 3H-PAF (0.32 nM) receptor binding with an IC50 of 22 nM, about one fifteenth that of triazolam (IC50= 320 nM). Diazepam and estazolam were inactive even at 1 /-cM (Fig. 4, Table 2 ).
Discussion
Etizolam, an anti-anxiety drug, potently inhibited PAF-induced aggregation of rabbit platelets. The effect was specific to PAF Other anti-anxiety drugs tested had no effect on PAF-induced ag gregation, indicating that the inhibitory activity of etizolam and triazolam on PAF induced aggregation had no relation with anti-anxietic activity.
Benzodiazepine receptors have been found in platelets and their roles on platelet func tions have been discussed (7) . Diazepam and flurazepam were reported to inhibit human platelet aggregation induced by ADP, AA or epinephrine at high concentrations (8) , suggesting that their anti-platelet activity was mediated by the benzodiazepine receptors. However, O'Beirne and Williams (9) indicated that human platelets do not possess de tectable binding sites for peripheral type benzodiazepines such as Ro 5-4864. Fur thermore, in this report, the anti-anxiety drugs tested which had a high affinity for benzo diazepine receptors (10) (12) and CV-3988 (13).
In conclusion, etizolam is a specific PAF receptor antagonist, specifically inhibiting PAF-induced aggregation of rabbit platelets. It may be useful in treating disorders caused by PAF and may be useful tool for studying the pathophysiological significance of PAF.
